Abstract: The present invention relates to methods and compositions for treating heart failure in a subject using histone deacetylase (HDAC) inhibitors and/or histone acetyltransferases (HAT) activators.

Abstract: A saddle fender bender for forming and maintaining a bend of approximately a ninety degree arc in a leather saddle fender lower forward portion that consists of a metal bar that is bent into an arc of approximately ninety degrees and includes tapped holes or internally threaded posts formed or attached, at spaced intervals along, the bar inner surface that align with, or fit through holes, formed through the fender and are each to receive a threaded end of a broad head bolt fitted and turned therein to where each bolt broad head undersurface engages and presses into the fender, maintaining the fender bender to the fender.

Abstract: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.